Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bachra Choufi.
Journal of Clinical Oncology | 2013
Gandhi Damaj; Remy Gressin; Krimo Bouabdallah; Guillaume Cartron; Bachra Choufi; Emmanuel Gyan; Anne Banos; Arnaud Jaccard; Sophie Park; Olivier Tournilhac; Jean-Marc Schiano-De Collela; Laurent Voillat; Bertrand Joly; Steven Le Gouill; Alain Saad; Pascale Cony-Makhoul; Jean-Pierre Vilque; Laurence Sanhes; Aline Schmidt-Tanguy; Michael Bubenheim; Roch Houot; Momar Diouf; Jean-Pierre Marolleau; Marie-Christine Béné; Antoine Martin; Thierry Lamy
PURPOSE To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas. PATIENTS AND METHODS Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma who progressed after one or more lines of prior chemotherapy received bendamustine at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS Of the 60 patients included, 27 (45%) were refractory to their last prior chemotherapy, and the median duration of the best previous response was 6.6 months. Histology was predominantly angioimmunoblastic lymphadenopathy and PTCL not otherwise specified. The disease was disseminated in the majority of patients (87%). The median number of previous lines of chemotherapy was one (range, one to three). Twenty patients (33%) received fewer than three cycles of bendamustine, mostly because of disease progression. In the intent-to-treat population, the ORR was 50%, including complete response in 17 patients (28%) and partial response in 13 patients (22%). Bendamustine showed consistent efficacy independent of major disease characteristics. The median values for DoR, PFS, and OS were 3.5, 3.6, and 6.2 months, respectively. The most frequent grade 3 to 4 adverse events were neutropenia (30%), thrombocytopenia (24%), and infections (20%). CONCLUSION Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.
British Journal of Haematology | 1998
Andrei Tchirkov; Michel Giollant; Françoise Tavernier; Georges BrianÇon; Olivier Tournilhac; Fabrice Kwiatkowski; Pierre Philippe; Bachra Choufi; François Demeocq; Philippe Travade; Paul Malet
There is a need for fast and sensitive methods to evaluate the response of patients with chronic myeloid leukaemia (CML) to interferon‐α (IFN‐α) therapy to complement cytogenetic analysis of Philadelphia (Ph) chromosome‐positive metaphases. We have used interphase FISH (fluorescence in situ hybridization) and competitive RT‐PCR (reverse transcriptase‐polymerase chain reaction) techniques for detection of BCR‐ABL‐positive cells to measure suppression of leukaemic clone in a series of 51 follow‐up samples from 24 CML patients undergoing IFN‐α treatment. Interphase FISH analysis of the malignant clone in bone marrow using BCR and ABL probes was found to be highly correlated to conventional G‐banding metaphase examination (r = 0.98). RT‐PCR quantification of BCR‐ABL mRNA transcripts in blood also showed a high degree of concordance with the proportion of Ph‐positive metaphases (r = 0.93). In addition, the degree of cytogenetic response did not influence the equivalence between karyotype analysis and molecular methods. We concluded that interphase FISH and competitive RT‐PCR provide reliable information on residual tumour burden and response to IFN‐α in CML patients. These molecular methods may significantly improve the efficiency of residual disease monitoring during IFN‐α therapy of CML.
Journal of Clinical Oncology | 2017
Catherine Thieblemont; Hervé Tilly; Maria Gomes da Silva; Rene-Olivier Casasnovas; Christophe Fruchart; Franck Morschhauser; Corinne Haioun; Julien Lazarovici; Anida Grosicka; Aurore Perrot; Judith Trotman; C. Sebban; Dolores Caballero; Richard Greil; Koen Van Eygen; Amos M. Cohen; Hugo Gonzalez; Reda Bouabdallah; Lucie Oberic; Bernadette Corront; Bachra Choufi; Armando López-Guillermo; John Catalano; Achiel Van Hoof; Josette Briere; José Cabeçadas; Gilles Salles; Philippe Gaulard; André Bosly; Bertrand Coiffier
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Methods Patients with previously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR after six or eight cycles of R-CHOP, and were randomly assigned to lenalidomide maintenance 25 mg/d or placebo for 21 days of every 28-day cycle for 24 months. The primary end point was progression-free survival (PFS). Results A total of 650 patients were randomly assigned. At the time of the primary analysis (December 2015), with a median follow-up of 39 months from random assignment, median PFS was not reached for lenalidomide maintenance versus 58.9 months for placebo (hazard ratio, 0.708; 95% CI, 0.537 to 0.933; P = .01). The result was consistent among analyzed subgroups (eg, male v female, age-adjusted International Prognostic Index 0 or 1 v 2 or 3, age younger than 70 v ≥ 70 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negative v positive). With longer median follow-up of 52 months (October 2016), overall survival was similar between arms (hazard ratio, 1.218; 95% CI, 0.861 to 1.721; P = .26). Most common grade 3 or 4 adverse events associated with lenalidomide versus placebo maintenance were neutropenia (56% v 22%) and cutaneous reactions (5% v 1%), respectively. Conclusion Lenalidomide maintenance for 24 months after obtaining a CR or PR to R-CHOP significantly prolonged PFS in elderly patients with DLBCL.
Haematologica | 2010
Charikleia Kelaidi; Aspasia Stamatoullas; Odile Beyne-Rauzy; Emmanuel Raffoux; Bruno Quesnel; Agnès Guerci; Francois Dreyfus; Sabine Brechignac; Christian Berthou; Thomas Prebet; Yosr Hicheri; Maya Hacini; Jacques Delaunay; Marie-Pierre Gourin; Jean-Marie Camo; Hacene Zerazhi; Anne-Laure Taksin; Laurence Legros; Bachra Choufi; Pierre Fenaux
Background There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice. Design and Methods We conducted a cross-sectional study of all patients with myelodysplastic syndromes attending 74 French centers in a 1-week period for inpatient admission, day-hospital care or outpatient visits. Results Nine hundred and seven patients were included; 67.3% had lower-risk myelodysplastic syndromes (International Prognostic Scoring System: low or intermediate-1). Karyotype had been analyzed in 82.5% of the cases and was more often of intermediate or poor risk in patients under 65 years old compared with those who were older. Red blood cell transfusions accounted for as many as 31.4% of the admissions. Endogenous erythropoietin level was less than 500 IU/L in 88% of the patients tested. Erythroid stimulating agents had been or were being used in 36.8% of the lower risk patients, iron chelation in 31% of lower risk patients requiring red blood cell transfusions and lenalidomide in 41% of lower risk patients with del 5q. High-dose chemotherapy, hypomethylating agents, low dose cytarabine and allogeneic stem cell transplantation had been or were being used in 14.8%, 31.1%, 8.8% and 5.1%, respectively, of higher-risk patients. Conclusions Karyotype is now assessed in most patients with myelodysplastic syndromes, and patients under 65 years old may have more aggressive disease. Apart from erythroid-stimulating agents and, in higher-risk myelodysplastic syndromes, hypomethylating agents, specific treatments are used in a minority of patients with myelodysplastic syndromes and red blood cell transfusions still represent the major reason for hospital admission.
Haematologica | 2016
Sylvain Thepot; Raouf Ben Abdelali; Sylvie Chevret; Aline Renneville; Odile Beyne-Rauzy; Thomas Prebet; Sophie Park; Aspasia Stamatoullas; Agnès Guerci-Bresler; Stéphane Cheze; Gérard Tertian; Bachra Choufi; Laurence Legros; jean Noel Bastie; Jacques Delaunay; Marie Pierre Chaury; Laurence Sanhes; Eric Wattel; Francois Dreyfus; Norbert Vey; Fatiha Chermat; Claude Preudhomme; Pierre Fenaux; Claude Gardin
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes of patients, all of them having the characteristics of this subset of lower-risk myelodysplastic syndrome, if randomly treated with azacitidine alone or azacitidine combined with epoetin-β. High-resolution cytogenetics and gene mutation analysis were performed at entry. The primary study endpoint was the achievement of red blood cell transfusion independence after six cycles. Ninety-eight patients were randomised (49 in each arm). Median age was 72 years. In an intention to treat analysis, transfusion independence was obtained after 6 cycles in 16.3% versus 14.3% of patients in the azacitidine and azacitidine plus epoetin-β arms, respectively (P=1.00). Overall erythroid response rate (minor and major responses according to IWG 2000 criteria) was 34.7% vs. 24.5% in the azacitidine and azacitidine plus epoetin-β arms, respectively (P=0.38). Mutations of the SF3B1 gene were the only ones associated with a significant erythroid response, 29/59 (49%) versus 6/27 (22%) in SF3B1 mutated and unmutated patients, respectively, P=0.02. Detection of at least one “epigenetic mutation” and of an abnormal single nucleotide polymorphism array profile were the only factors associated with significantly poorer overall survival by multivariate analysis. The transfusion independence rate observed with azacitidine in this lower-risk population, but resistant to erythropoietic stimulating agents, was lower than expected, with no observed benefit of added epoetin, (clinicaltrials.gov identifier: 01015352).
Leukemia & Lymphoma | 2016
Anne-Claire Gac; Nabih Azar; Etienne Daguindau; Guillaume Cartron; Luc Matthieu Fornecker; Emmanuel Gyan; Florence Broussais-Guillaumot; Reda Garidi; Bachra Choufi; Sylvain Chantepie; Marie-Christine Béné; Romain Guièze; Fontanet Bijou; Remy Gressin; Sandy Amorim; Gandhi Damaj
Abstract Bendamustine is used in the treatment of different relapsing or refractory subtypes of lymphoma. Its impact on the yield of peripheral blood stem cells is not well known. Twenty three patients who received bendamustine followed immediately or after another chemotherapy by stem cell mobilization (SCM) were included. The patients were divided into two groups: group 1 (n=17), in whom SCM was performed immediately after bendamustine chemotherapy, and group 2 (n=6), in whom SCM was performed after another cycle of chemotherapy. The success rate of mobilization after Bendamustine+/−plerixafor was 36% (eight cytapheresis succeeded for a total number of 22 cytapheresis); and 75% after other approaches (chemotherapy based or steady state) used for patients who received bendamustine previously. Although bendamustine used alone was not an effective drug to mobilize stem cells, this agent does not seem to have detrimental effects on subsequent SCM.
Oncotarget | 2016
Emilie Reboursiere; Fabien Le Bras; Charles Herbaux; Emmanuel Gyan; Aline Clavert; Franck Morschhauser; Sandra Malak; David Sibon; Florence Broussais; Thorsten Braun; Luc-Matthieu Fornecker; Reda Garidi; Sabine Tricot; Roch Houot; Bertrand Joly; Wajed Abarah; Bachra Choufi; Anne-Dominique Pham; Anne-Claire Gac; Christophe Fruchart; Emilie Marin; Violaine Safar; Anne Parcelier; Hervé Maisonneuve; Emmanuel Bachy; Guillaume Cartron; Arnaud Jaccard; Olivier Tournilhac; Cédric Rossi; Luciane Schirmer
Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients. Between November 2009 and March 2015, 138 PTCL patients were treated with bendamustine in 27 centers. Population median age was 64 (28-89) years with male/female ratio of 1.4. There were mainly angio-immunoblastic (AITL = 71), PTCL-not otherwise specified (PTCL-NOS = 40) and anaplastic large cell lymphoma (ALCL = 8). The majority of patients (96%) had disseminated disease and extranodal localizations (77%). Median number of chemotherapy lines prior to bendamustine was 2 (1-8). Median duration of response (DoR) after the last chemotherapy prior to bendamustine was 4.3 months (1-70) and 50% of patients had refractory disease. Median number of administered bendamustine cycles was 2 (1-8) and 72 patients (52%) received less than 3 mostly because of disease progression. Median dose was 90 (50-150) mg/m². Overall response rate (ORR) was 32.6% with complete response (CR) rate of 24.6% and median DoR was 3.3 months (1-39). AITL patients were more sensitive than PTCL-NOS patients (ORR: 45.1 versus 20%, p = 0.01). Median PFS and OS were 3.1 (0.2-46.3) and 4.4 (0.2-55.4) months. On multivariate analysis, refractory disease (p = 0.001) and extranodal localization (p = 0.028) adversely influenced ORR. Grade 3-4 thrombocytopenia, neutropenia and infections were reported in 22, 17 and 23% of cases respectively. Bendamustine as single agent could be considered as a therapeutic option for relapsed or refractory PTCL, particularly in chemosensitive or AITL patients. Combinations of bendamustine with other drugs warrant further evaluation.
Blood | 2003
Mohamad Mohty; Jacques-Olivier Bay; Catherine Faucher; Bachra Choufi; Karin Bilger; Olivier Tournilhac; Norbert Vey; Anne-Marie Stoppa; Diane Coso; Christian Chabannon; Patrice Viens; Dominique Maraninchi; Didier Blaise
Blood | 2004
Didier Blaise; Jacques Olivier Bay; Catherine Faucher; Mauricette Michallet; Jean-Michel Boiron; Bachra Choufi; Jean-Yves Cahn; Nicole Gratecos; Jean-Jacques Sotto; Sylvie François; Joel Fleury; Mohamad Mohty; Christian Chabannon; Karin Bilger; Gwenaelle Gravis; Frédéric Viret; Anne Chantal Braud; Valerie Jeanne Bardou; Dominique Maraninchi; Patrice Viens
Blood | 2010
Simone Boehrer; Odile Beyne-Rauzy; Thomas Prebet; Sophie Park; Agnès Guerci; Aspasia Stamatoulas; M.P. Chaury; Tony Jernival; Laurence Sanhes; Gérard Tertian; Stéphane Cheze; Eng-Mong Lim; Bachra Choufi; Denis Caillot; Eric Wattel; Jacques Delaunay; Laurence Legros; Fatiha Chermat; Françoise Isnard; Nathalie Cambier; Borhane Slama; Lydia Roy; Gandhi Damaj; Emmanuel Raffoux; F. Dreyfus; Christian Recher; Norbert Vey; Sylvie Chevret; Pierre Fenaux; Claude Gardin